Glucose toxicity: the leading actor in the pathogenesis and clinical history of type 2 diabetes - mechanisms and potentials for treatment.
about
Degeneration of Dopaminergic Neurons Due to Metabolic Alterations and Parkinson's DiseaseHyperglycemic Stress and Carbon Stress in Diabetic GlucotoxicityEfficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitusFructose Metabolism and Relation to Atherosclerosis, Type 2 Diabetes, and ObesityVitamin D deficiency: a new risk factor for type 2 diabetes?Mondo/ChREBP-Mlx-regulated transcriptional network is essential for dietary sugar tolerance in DrosophilaCooperative anti-diabetic effects of deoxynojirimycin-polysaccharide by inhibiting glucose absorption and modulating glucose metabolism in streptozotocin-induced diabetic miceNecrotizing fasciitis in patients with diabetes mellitus: clinical characteristics and risk factors for mortality.Altered expression of base excision repair genes in response to high glucose-induced oxidative stress in HepG2 hepatocytesBone metabolism and hand grip strength response to aerobic versus resistance exercise training in non-insulin dependent diabetic patients.1-deoxynojirimycin inhibits glucose absorption and accelerates glucose metabolism in streptozotocin-induced diabetic miceRNA-sequencing analysis of high glucose-treated monocytes reveals novel transcriptome signatures and associated epigenetic profilesCaenorhabditis elegans PAQR-2 and IGLR-2 Protect against Glucose Toxicity by Modulating Membrane Lipid Composition.β-Cell Glucose Sensitivity Is Linked to Insulin/Glucagon Bihormonal Cells in Nondiabetic Humans.Resveratrol protects DAergic PC12 cells from high glucose-induced oxidative stress and apoptosis: effect on p53 and GRP75 localization.Effect of a short-term exercise program on glycemic control measured by fructosamine test in type 2 diabetes patients.Insulin resistance alters islet morphology in nondiabetic humans.Interactions between mesenchymal stem cells, adipocytes, and osteoblasts in a 3D tri-culture model of hyperglycemic conditions in the bone marrow microenvironment.Antioxidant properties of drugs used in Type 2 diabetes management: could they contribute to, confound or conceal effects of antioxidant therapy?The size of adrenal incidentalomas correlates with insulin resistance. Is there a cause-effect relationship?Effect of Betula pendula Leaf Extract on α-Glucosidase and Glutathione Level in Glucose-Induced Oxidative Stress.Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to dateControlling the complications of diabetes: it's about the sugar.The need for identifying standardized indices for measuring glucose variability.25-Hydroxyvitamin D concentration correlates with insulin-sensitivity and BMI in obesity.Multiple fractures and impaired bone metabolism in Wolfram syndrome: a case report.High intake of dietary tyramine does not deteriorate glucose handling and does not cause adverse cardiovascular effects in mice.Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus.
P2860
Q26750370-6EE70886-724C-4650-8033-9BD467D145D8Q26773988-34067DB5-E508-449B-AEE0-95345E101177Q26782225-62EBCA20-D432-40D5-9378-DEA54EE40184Q26801099-B214C353-1EE1-4D6C-8704-76732B16955DQ26864727-F8C16F9E-D1E1-4891-BE8A-42FABFDA2830Q27323381-2D91ED21-3ACD-4B65-AD95-A083489F5CB5Q28533699-8C789260-EB57-4F5A-8B7F-8AA872E2CE9EQ35805602-3DA9C774-98E4-4EDF-B50C-F0F18B656B4BQ36577536-CC6627EA-D473-46A2-A5CE-F2CDF3E650C3Q36612785-24ADE0FE-06B2-4A58-A426-18F0F7F1226AQ36722448-EB2BDECA-4D45-4CF6-A420-A27C13013BF5Q36787367-792F51F1-08CC-445C-9AF7-6649DAF3CA12Q36802565-E85BA2DF-F62C-4F7D-BB67-423A0CD670DDQ36935383-B5B501BB-5850-48BA-A258-85913066BAC7Q37470082-D8D77EEA-6053-4195-B837-5F8BC9A685CBQ37586438-63DCBF3B-9677-4A09-9A28-B6CFF5226740Q37597046-F5D5EE73-C097-4CC2-9CCF-9E14C791F784Q38496332-6105C0F8-9512-4D93-9E32-79FD4D72D371Q38780360-3F326FCB-DE4E-45F5-8B9D-ABBCF2A1FEECQ39283863-C54B4BAC-18DA-404B-9776-16700D1F6E1AQ41138380-973ECA86-DDFC-488B-BBFB-935BE7B163A5Q42373168-126FC081-6EBC-479E-A7F9-4ED921E927B3Q42552617-CEF449D7-3E16-41F2-976D-AA63161DE230Q42555071-75221C81-D171-4C1D-9908-487038440AC1Q43164533-A5B43329-2C20-4085-BA29-9F39D5D9D8FAQ47152781-36464D60-116B-496D-9848-94A368F6634CQ51293187-408E7C16-BD0D-4460-89FF-4FFF8CD1A2F6Q51354362-131A8468-5D73-409D-9AF0-693F01CAE326
P2860
Glucose toxicity: the leading actor in the pathogenesis and clinical history of type 2 diabetes - mechanisms and potentials for treatment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Glucose toxicity: the leading ...... and potentials for treatment.
@en
Glucose toxicity: the leading ...... and potentials for treatment.
@nl
type
label
Glucose toxicity: the leading ...... and potentials for treatment.
@en
Glucose toxicity: the leading ...... and potentials for treatment.
@nl
prefLabel
Glucose toxicity: the leading ...... and potentials for treatment.
@en
Glucose toxicity: the leading ...... and potentials for treatment.
@nl
P921
P1476
Glucose toxicity: the leading ...... and potentials for treatment.
@en
P2093
P304
P356
10.1016/J.NUMECD.2009.03.018
P577
2009-05-09T00:00:00Z